BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36815785)

  • 21. Human papillomavirus 16 minor capsid protein L2 helps capsomeres assemble independently of intercapsomeric disulfide bonding.
    Ishii Y; Ozaki S; Tanaka K; Kanda T
    Virus Genes; 2005 Dec; 31(3):321-8. PubMed ID: 16175337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.
    Bissett SL; Godi A; Fleury MJ; Touze A; Cocuzza C; Beddows S
    J Virol; 2015 Aug; 89(15):7748-57. PubMed ID: 25995264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HPV16 L2 improves HPV16 L1 gene delivery as an important approach for vaccine design against cervical cancer.
    Namvar A; Bolhassani A; Hashemi M
    Bratisl Lek Listy; 2016; 117(3):179-84. PubMed ID: 26925750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.
    Schellenbacher C; Roden R; Kirnbauer R
    J Virol; 2009 Oct; 83(19):10085-95. PubMed ID: 19640991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study of infectious virus production from HPV18/16 capsid chimeras.
    Chen HS; Bromberg-White J; Conway MJ; Alam S; Meyers C
    Virology; 2010 Sep; 405(2):289-99. PubMed ID: 20598725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of human papillomavirus (HPV) type 16 capsid proteins with HPV DNA requires an intact L2 N-terminal sequence.
    Zhou J; Sun XY; Louis K; Frazer IH
    J Virol; 1994 Feb; 68(2):619-25. PubMed ID: 8289365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topography of the Human Papillomavirus Minor Capsid Protein L2 during Vesicular Trafficking of Infectious Entry.
    DiGiuseppe S; Keiffer TR; Bienkowska-Haba M; Luszczek W; Guion LG; Müller M; Sapp M
    J Virol; 2015 Oct; 89(20):10442-52. PubMed ID: 26246568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in human papillomavirus type 16 L1 hypervariable surface-exposed loops affect L2 binding and DNA encapsidation.
    Faust H; Dillner J
    J Gen Virol; 2013 Aug; 94(Pt 8):1841-1849. PubMed ID: 23658208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
    Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
    Sci Rep; 2019 Oct; 9(1):15225. PubMed ID: 31645650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An L2 SUMO interacting motif is important for PML localization and infection of human papillomavirus type 16.
    Bund T; Spoden GA; Koynov K; Hellmann N; Boukhallouk F; Arnold P; Hinderberger D; Florin L
    Cell Microbiol; 2014 Aug; 16(8):1179-200. PubMed ID: 24444361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. L1 and L2 gene polymorphisms in HPV-58 and HPV-33: implications for vaccine design and diagnosis.
    Chen Z; Jing Y; Wen Q; Ding X; Zhang S; Wang T; Zhang Y; Zhang J
    Virol J; 2016 Oct; 13(1):167. PubMed ID: 27717385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
    Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
    PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.
    Gambhira R; Jagu S; Karanam B; Gravitt PE; Culp TD; Christensen ND; Roden RB
    J Virol; 2007 Nov; 81(21):11585-92. PubMed ID: 17715230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Furin Cleavage of L2 during Papillomavirus Infection: Minimal Dependence on Cyclophilins.
    Bronnimann MP; Calton CM; Chiquette SF; Li S; Lu M; Chapman JA; Bratton KN; Schlegel AM; Campos SK
    J Virol; 2016 Jul; 90(14):6224-6234. PubMed ID: 27122588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimized production strategy of the major capsid protein HPV 16L1 non-assembly variant in E. coli.
    Roos N; Breiner B; Preuss L; Lilie H; Hipp K; Herrmann H; Horn T; Biener R; Iftner T; Simon C
    Protein Expr Purif; 2020 Nov; 175():105690. PubMed ID: 32681956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. APOBEC3A and 3C decrease human papillomavirus 16 pseudovirion infectivity.
    Ahasan MM; Wakae K; Wang Z; Kitamura K; Liu G; Koura M; Imayasu M; Sakamoto N; Hanaoka K; Nakamura M; Kyo S; Kondo S; Fujiwara H; Yoshizaki T; Mori S; Kukimoto I; Muramatsu M
    Biochem Biophys Res Commun; 2015 Feb; 457(3):295-9. PubMed ID: 25576866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.
    Ahmed AI; Bissett SL; Beddows S
    Infect Genet Evol; 2013 Aug; 18():151-9. PubMed ID: 23722024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-risk HPV L1 capsid protein as a marker of cervical intraepithelial neoplasia in high-risk HPV-positive women with minor cytological abnormalities.
    Norman I; Hjerpe A; Andersson S
    Oncol Rep; 2013 Aug; 30(2):695-700. PubMed ID: 23756570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.